Reflects Another Desperate Attempt to Mislead and Distract Samaritan
Shareholders
Las Vegas, Nev., March 16 /PRNewswire-FirstCall/ --
Samaritan Pharmaceuticals Inc. (OTC Bulletin Board: SPHC) today responded to a
Cortisol Medical Research, Inc. "fictitious press release," alleging false and
misleading statements made solely to damage the reputation of Samaritan
Pharmaceuticals.
Dr. Janet Greeson, CEO of Samaritan stated, "The negative statements in
this fictitious release are categorically false and reflects another desperate
attempt to damage the reputation of Samaritan, its officers and attorneys.
Samaritan intends to contact the appropriate authorities and will take all the
necessary legal action to protect our integrity and reputation. Samaritan
shareholders should be assured that its officers and directors stand strong
and our commitment to Samaritan has never been stronger."
About Samaritan Pharmaceuticals
Samaritan Pharmaceuticals, in collaboration with Georgetown University,
strives to commercialize breakthrough scientific innovation. Samaritan is
focused on the development of novel therapeutics for Alzheimer's, CNS
Disorders, Cancer, Cholesterol and HIV. Samaritan's patented pipeline
includes: a completed HIV Phase II trial with positive data being prepared for
FDA submission; an Animal (rat) model for Alzheimer's disease; Novel
Neuroprotective compounds; a Peptide to bind cholesterol; an Alzheimer's and
Breast Cancer Diagnostic/Theranostic; and a series of novel compounds.
Disclaimer
The company disclaims any information that is created by an outside party
and endorses only information that is communicated by its press releases,
filings and Web site. This news release contains forward-looking statements
that reflect management's current beliefs about the potential for its drug
candidates, science and technology. However, as with any biopharmaceutical
under development, there are significant risks and uncertainties in the
process of development and regulatory review. There are no guarantees that
products will prove to be commercially successful. For additional information
about the factors that affect the company's business, please read the
company's latest Form 10-K filed April 26, 2002. The company undertakes no
duty to update forward-looking statements.
Contact: Samaritan Pharmaceuticals, Inc.,
702/735-7001, Fax 702/737-7016
Gene Boyle, Business Development, Email GeneBoyle@aol.com
Doug Bessert, Investor Relations, Email DougBessert@aol.com
To receive future press releases and newsletters automatically, or for
more information, visit our Web site at http://www.samaritanpharmaceuticals.com.
SOURCE Samaritan Pharmaceuticals, Inc.
 back to top
Related links:
http://www.samaritanpharma.com
Company News On-Call:
http://www.prnewswire.com/comp/158311.html
CONTACT:
Gene Boyle, Business Development,
GeneBoyle@aol.com, or Doug Bessert, Investor Relations,
DougBessert@aol.com, both of Samaritan Pharmaceuticals, Inc.,
+1-702-735-7001, Fax +1-702-737-7016
|
